NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D ...

If funding stops, those gains simply won’t materialize. There’s good reason for concern: Overall investment in R&D for neglected diseases in 2023 was $3.7 billion, down from a high of $4.7 ...

The Fourth Industrial Revolution presents both opportunities and challenges for Vietnam. To secure its place among leading ...

Nanotech involves working with tiny particles which are about the size of molecules. This field is being used to improve ...

South Africa’s research and development funding, human resource development and infrastructure agency, the National Research Foundation (NRF), and the FirstRand Empowerment Foundation (FREF), have ...

Industry-led aviation and railways partnerships run nine out of the ten largest Horizon Europe innovation projects, at least ...

Japan began negotiations to join Horizon Europe. If successful, it would mark the first time the country has been fully ...

and Israel’s 5.71% Low R&D funding has a direct bearing on the Indian healthcare ecosystem, which hampers the development of new drugs, medical devices, or treatments Philanthropic organisations ...

Royalty Pharma (RPRX) announced that it has entered into an agreement with Biogen (BIIB) to provide research and development funding of up to $250M for litifilimab, a first-in-class ...